{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:08:47Z","timestamp":1789160927297,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bmcl.2022.128883","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T11:38:42Z","timestamp":1657366722000},"page":"128883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay"],"prefix":"10.1016","volume":"73","author":[{"given":"Qiqi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongya","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daohai","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128883_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bmcl.2022.128883_b0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2022.128883_b0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2022.128883_b0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2009.358","article-title":"Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer","volume":"29","author":"DeBerardinis","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bmcl.2022.128883_b0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1084\/jem.102.1.37","article-title":"The specific amino acid requirements of a human carcinoma cell (Stain HeLa) in tissue culture","volume":"102","author":"Eagle","year":"1955","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmcl.2022.128883_b0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway","volume":"496","author":"Son","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2022.128883_b0035","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1186\/bcr2154","article-title":"Targeting aspartate aminotransferase in breast cancer","volume":"10","author":"Thornburg","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128883_b0040","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.bbrc.2016.04.061","article-title":"Enhancing doxorubicin efficacy through inhibition of aspartate transaminase in triple-negative breast cancer cells","volume":"473","author":"Yang","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmcl.2022.128883_b0045","doi-asserted-by":"crossref","unstructured":"Zhou X, Curbo S, Li F, Krishnan S, Karlsson A. Inhibition of glutamate oxaloacetate transaminase 1 in cancer cell lines results in altered metabolism with increased dependency of glucose. BMC Cancer. May 11 2018;18(1):55. doi: 10.1186\/s12885-018-4443-1.","DOI":"10.1186\/s12885-018-4443-1"},{"key":"10.1016\/j.bmcl.2022.128883_b0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2017.04.029","article-title":"GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells","volume":"400","author":"Abrego","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmcl.2022.128883_b0055","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/mc.22878","article-title":"miR-9 regulates ferroptosis by targeting glutamic-oxaloacetic transaminase GOT1 in melanoma","volume":"57","author":"Zhang","year":"2018","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.bmcl.2022.128883_b0060","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00280-017-3282-0","article-title":"Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil","volume":"79","author":"Hong","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bmcl.2022.128883_b0065","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1021\/acs.biochem.8b00914","article-title":"Biochemical characterization and structure-based mutational analysis provide insight into the binding and mechanism of action of novel aspartate aminotransferase inhibitors","volume":"57","author":"Holt","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2022.128883_b0070","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1016\/j.bmcl.2018.04.061","article-title":"Discovery and optimization of aspartate aminotransferase 1 inhibitors to target redox balance in pancreatic ductal adenocarcinoma","volume":"28","author":"Anglin","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128883_b0075","doi-asserted-by":"crossref","unstructured":"Sun W, Luan S, Qi C, et al. Aspulvinone O, a natural inhibitor of GOT1 suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism. Cell Commun Signal. Aug 30 2019;17(1):111. doi:10.1186\/s12964-019-0425-4.","DOI":"10.1186\/s12964-019-0425-4"},{"key":"10.1016\/j.bmcl.2022.128883_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103315","article-title":"Adapalene inhibits ovarian cancer ES-2 cells growth by targeting glutamic-oxaloacetic transaminase 1","volume":"93","author":"Wang","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2022.128883_b0085","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bbrc.2019.11.130","article-title":"A covalent small molecule inhibitor of glutamate-oxaloacetate transaminase 1 impairs pancreatic cancer growth","volume":"522","author":"Yoshida","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmcl.2022.128883_b0090","doi-asserted-by":"crossref","unstructured":"Yan S, Qi C, Song W, et al. Discovery of GOT1 Inhibitors from a Marine-Derived Aspergillus terreus That Act against Pancreatic Ductal Adenocarcinoma. Mar Drugs. Oct 20 2021;19(11). doi: 10.3390\/md19110588.","DOI":"10.3390\/md19110588"},{"key":"10.1016\/j.bmcl.2022.128883_b0095","doi-asserted-by":"crossref","unstructured":"Yang Y, Zheng M, Han F, et al. Ziprasidone suppresses pancreatic adenocarcinoma cell proliferation by targeting GOT1 to trigger glutamine metabolism reprogramming. J Mol Med (Berl). Feb 25 2022. doi: 10.1007\/s00109-022-02181-8.","DOI":"10.21203\/rs.3.rs-604303\/v1"},{"key":"10.1016\/j.bmcl.2022.128883_b0100","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1159\/000510433","article-title":"Genotype-guided hydralazine therapy","volume":"51","author":"Collins","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.bmcl.2022.128883_b0105","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"Macarron","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2022.128883_b0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pep.2015.05.010","article-title":"Expression, purification and preliminary crystallographic studies of human glutamate oxaloacetate transaminase 1 (GOT1)","volume":"113","author":"Jiang","year":"2015","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.bmcl.2022.128883_b0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pisc.2013.12.001","article-title":"Considerations for the design and reporting of enzyme assays in high-throughput screening applications","volume":"1","author":"Acker","year":"2014","journal-title":"Perspect Sci"},{"key":"10.1016\/j.bmcl.2022.128883_b0120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1042\/bj1710771","article-title":"The reaction of amino-oxyacetate with pyridoxal phosphate-dependent enzymes","volume":"171","author":"John","year":"1978","journal-title":"Biochem J"},{"key":"10.1016\/j.bmcl.2022.128883_b0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.bmcl.2022.128883_b0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-62703-758-7_4","article-title":"Reversible mechanisms of enzyme inhibition and resulting clinical significance","volume":"1113","author":"Ring","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bmcl.2022.128883_b0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.abb.2013.10.002","article-title":"Aspartate aminotransferase: an old dog teaches new tricks","volume":"544","author":"Toney","year":"2014","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.bmcl.2022.128883_b0140","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1055\/s-0033-1345163","article-title":"The inhibition of monoamine oxidase by esomeprazole","volume":"63","author":"Petzer","year":"2013","journal-title":"Drug Res (Stuttg)"},{"key":"10.1016\/j.bmcl.2022.128883_b0145","doi-asserted-by":"crossref","unstructured":"Kremer DM, Nelson BS, Lin L, et al. GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis. Nat Commun. Aug 11 2021;12(1):4860. doi: 10.1038\/s41467-021-24859-2.","DOI":"10.1038\/s41467-021-24859-2"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:45:36Z","timestamp":1760773536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22003596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":29,"alternative-id":["S0960894X22003596"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128883","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128883"}}